Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hall, C.
Right arrow Articles by Iatropoulos, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hall, C.
Right arrow Articles by Iatropoulos, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Methotrexate: Assessment of In Vivo Clastogenicity and Carcinogenicity

Claudette Hall

Wilbur G. Malcom Toxicology Laboratories, Medical Research Division, American Cyanamid Co., Pearl River, New York 10965

Philip Tnham

Wilbur G. Malcom Toxicology Laboratories, Medical Research Division, American Cyanamid Co., Pearl River, New York 10965

Madhu Manandhar

Wilbur G. Malcom Toxicology Laboratories, Medical Research Division, American Cyanamid Co., Pearl River, New York 10965

Maria Cheng

Wilbur G. Malcom Toxicology Laboratories, Medical Research Division, American Cyanamid Co., Pearl River, New York 10965

John F. Noble

Wilbur G. Malcom Toxicology Laboratories, Medical Research Division, American Cyanamid Co., Pearl River, New York 10965

Michael Iatropoulos

Wilbur G. Malcom Toxicology Laboratories, Medical Research Division, American Cyanamid Co., Pearl River, New York 10965

The genotoxic and oncogenic potentials of methotrexate were studied in Sprague-Dawley rats. The rats received 0.1, 0.2, or 0.4 mg/kg of methotrexate as dietary admixtures on a 5 days on, 9 days off, regimen for 23 months. In the females of the high-dose group, there was a significant increase in mortality starting at 18 months. Significant increases in the number of rats with focal pulmonary interstitial fibrosis were seen in both sexes at the high-dose level. At the mid-and high-dose levels of both sexes, there was a significantly increased number of rats with myeloid and erythroid bone marrow hypoplasia. There was no evidence of either early onset or increased incidence of any tumor type in the treatment groups. Therefore, it is concluded that methotrexate does not have oncogenic potential. Also, at terminal sacrifice, bone marrow cells were harvested from selected animals on the last day of the 5-day dosing cycle and cytogenetic evaluation was performed. No significant increase in chromosomal aberrations was seen in any dose group relative to the control group. This observation further substantiates the absence of oncogenic potential due to methotrexate in rats.

Toxicologic Pathology, Vol. 16, No. 1, 10-21 (1988)
DOI: 10.1177/019262338801600102
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?